Download PDF
Exp Clin Endocrinol Diabetes 2010; 118(10): 760-763
DOI: 10.1055/s-0030-1253419
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

H. Bode1 , M. Seiz2 , A. Lammert1 , M. A. Brockmann3 , W. Back4 , H.-P. Hammes1 , C. Thomé2
  • 1V. Medizinische Klinik, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Theodor-Kutzer-Ufer, Mannheim, Germany
  • 2Neurochirurgische Klinik, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Theodor-Kutzer-Ufer, Mannheim, Germany
  • 3Institut für Neuroradiologie, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Theodor-Kutzer-Ufer, Mannheim, Germany
  • 4Pathologisches Institut, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Theodor-Kutzer-Ufer, Mannheim, Germany
Further Information

Publication History

received 13.01.2010 first decision 25.02.2010

accepted 15.04.2010

Publication Date:
21 May 2010 (online)

Also available at
    Permissions and Reprints

Abstract

Pituitary carcinomas are rare and neurosurgically challenging lesions, as they commonly relapse after surgical removal. Their prognosis is dismal due to their limited response to radiotherapy and chemotherapy. In recent studies, temozolomide was administered in very few patients with partial effects. We report a patient with an ACTH-secreting pituitary carcinoma and widespread intracranial, spinal and systemic metastases despite repeated surgical treatment, bilateral adrenalectomy, medical treatment and radiotherapy. Additionally to chemotherapy with temozolomide, the patient received SOM230 as salvage therapy with an improvement of the patient's clinical status, and a reduction of ACTH levels. After 12 months of combination therapy a sustained tumor control was achieved and persisted upon monotherapy with SOM230 for more than 9 months thereafter. Thus, temozolomide in combination with SOM230 seems to be promising in patients with ACTH-secreting metastasized pituitary carcinoma.

Key words

cancer - pituitary adenoma - Cushing - hormones

References

  • 1 Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature.  Neurosurg Focus. 2004;  16 Article7
    Google Scholar
  • 2 Sidibé EH. Pituitary carcinoma. Anatomic and clinical features of cases reported in literature.  Neurochirurgie. 2007;  53 284-288
    Google Scholar
  • 3 Kaltsas GA, Nomikos P, Kontogeorgos G. et al . CLINICAL REVIEW: Diagnosis and Management of Pituitary Carcinomas.  J Clin Endocrinol Metab. 2005;  90 3089-3099
    Google Scholar
  • 4 Gaffey TA, Scheithauer BW, Lloyd RV. et al . Corticotroph carcinoma of the pituitary: a clinicopathological study.  J Neurosurg. 2002;  96 352-360
    Google Scholar
  • 5 Pernicone PJ, Scheithauer BW, Sebo TJ. et al . Pituitary Carcinoma A Clinicopathologic Study of 15 Cases.  Cancer. 1997;  79 804-812
    Google Scholar
  • 6 Landman RE, Horwith M, Peterson RE. et al . Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature.  J Clin Endocrinol Metab. 2002;  87 3084-3089
    Google Scholar
  • 7 Stupp R, Mason WP, van den Bent MJ. et al . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.  N Engl J Med. 2005;  352 978-996
    Google Scholar
  • 8 Fadul CE, Kominsky AL, Meyer LP. et al . Long-term response of pituitary carcinoma to temozolomide. Report of two cases.  J Neurosurg. 2006;  105 621-626
    Google Scholar
  • 9 Lim S, Shahinian H, Maya MM. et al . Temozolomide: a novel treatment for pituitary carcinoma.  Lancet Oncol. 2006;  7 518-520
    Google Scholar
  • 10 Hagen C, Schroeder HD, Hansen S. et al . Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.  Eur J Endocrinol. 2009;  161 631-637
    Google Scholar
  • 11 Moyes VJ, Alusi G, Sabin HI. et al . Treatment of Nelson's syndrome with temozolomide.  Eur J Endocrinol. 2009;  160 115-119
    Google Scholar
  • 12 Mohammed S, Kovacs K, Mason W. et al . xUse of temozolomide in aggressive pituitary tumors: case report. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD.  Neurosurgery. 2009;  64 E773–E774
    Google Scholar
  • 13 Guzel A, Tatli M, Senturk S. et al . Pituitary Carcinoma Presenting with Multiple Metastases: Case Report.  J Child Neurol. 2008;  23 1467-1471
    Google Scholar
  • 14 Boscaro M, Ludlam WH, Atkinson B. et al . Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.  J Clin Endocrinol Metab. 2009;  94 115-122
    Google Scholar
  • 15 Batista DL, Zhang X, Gejman R. et al . The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.  J Clin Endocrinol Metab. 2006;  91 4482-4488
    Google Scholar
  • 16 Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications.  Mol Cell Endocrinol. 2008;  286 69-74
    Google Scholar
  • 17 Hofland LJ, van der Hoek J, Feelders R. et al . The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.  2005;  152 645-654
    Google Scholar

Correspondence

Dr. H. Bode

V. Medizinische Klinik

Universitätsmedizin Mannheim

Theodor-Kutzer-Ufer 1–3

68167 Mannheim

Germany

Phone: +49/621/383 2317

Fax: +49/621/383 2159

Email: hinrich.bode@umm.de

      >